Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-CTR-FAPI in advanced solid tumors
NCT07229768Phase 1Recruiting
- Start
- Oct 2025
- Primary completion
- Nov 2026
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-CTR-FAPI in pancreatic cancer (PC), breast cancer and soft tissue sarcoma (STS). Primary endpoint: Adverse Events at 12 months. Started Oct 2025; status: recruiting.
02
Drugs
177Lu-CTR-FAPI
03
Conditions
pancreatic cancer (PC)breast cancersoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07229768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229768.